![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.pharmaceutical-technology.com/news/formosa-tabuk-ophthalmic-suspension/
https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-announces-licensing-agreement-with-tabuk-pharmaceuticals-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery-302139905.html
https://www.reuters.com/business/healthcare-pharmaceuticals/gsks-new-hiv-drug-formula-could-support-longer-dosing-intervals-2024-03-04/
https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-announces-licensing-agreement-with-cristalia-for-the-commercialization-of-app13007-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery-302045280.html
https://www.fiercebiotech.com/biotech/formosa-fresh-eyenovia-deal-sells-brazilian-rights-near-approval-eye-drug
https://www.biospectrumasia.com/news/25/22889/taiwan-based-formosa-pharma-inks-86-m-worth-ophthalmology-deal-with-american-firm-eyenovia.html
https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-announces-licensing-agreement-with-eyenovia-inc-for-the-commercialization-of-app13007-for-the-treatment-of-inflammation-and-pain-following-ocular-surgery-301901739.html
https://www.pharmaceutical-technology.com/news/formosa-aimmax-fda-pain-therapy/
https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-and-aimmax-therapeutics-announce-the-nda-submission-to-the-us-fda-for-app13007-for-the-treatment-of-post-operative-inflammation-and-pain-following-ocular-surgery-301815496.html
https://www.prnewswire.com/news-releases/formosa-pharmaceuticals-announces-development-collaboration-agreement-with-eyenovia-301746479.html